Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that enhancements in the uptake of adenovectors can be successfully applied to improve the uptake or therapeutic effects of Generx in human patients; that Generx can be successfully advanced in clinical studies outside of the U.S.; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the regulatory or commercialization activities of Generx in the U.S. or other markets; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that ar
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... N.C. By altering the genetic makeup of normally ... cells capable of generating and passing electrical current. ... treating diseases of the nervous system or the heart, ... to communicate with adjacent cells in order to function ...
... gene therapy into an arterial wall effectively protects the ... The promising results, published July 19 in the journal ... In atherosclerosis, fatty lesions called plaques form ... narrows arteries, thereby restricting blood flow and causing chest ...
... and Providence cities scattered across the eastern half ... all have coal-fired power plants. A new study from ... is among the first to investigate mercury deposits in ... The study, which appears in the July 2011 issue ...
Cached Biology News:Engineering excitable cells for studies of bioelectricity and cell therapy 2Engineering excitable cells for studies of bioelectricity and cell therapy 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 2Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 4Soil samples reveal urban mercury footprints 2
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Sales in the Third Quarter up by 7.2% to EUR268.0m, ... Third Quarter of 2008,From EUR7.4m to EUR16.5m, - Sales ... Axel Herberg Confirms the Outlook for 2008, Gerresheimer AG ... the third quarter of 2008. Overall, sales by the,globally operating ...
... October 2008] Recent research from the Swedish medical university ... stem cells discoveries that contradict previous findings. The ... show amongst other things, that hair follicle stem cells ... tissue. , "The stem cells don,t behave ...
... Based on its recent,analysis of the bone healing ... the 2008 North American Frost & Sullivan Award ... Extender and Substitute,scaffold. InQu represents the first commercial ... platform technology., Although spinal fusions and other ...
Cached Biology Technology:Gerresheimer Substantially Increases Quarterly Operating Profit 2Gerresheimer Substantially Increases Quarterly Operating Profit 3Gerresheimer Substantially Increases Quarterly Operating Profit 4Gerresheimer Substantially Increases Quarterly Operating Profit 5Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 2Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 4
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Synthetic peptide derived from the C-terminal region ... kinase C zeta isoform (PKCzeta). Specificity: ... protein. Recognizes PKCzeta and PKMzeta (PKCzeta ... Reactivity: Mouse Rat (positive controls: mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: